Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis/Penn To Research Chimeric Antigen Receptor Immunotherapies

This article was originally published in The Pink Sheet Daily

Executive Summary

The Anglo/Swiss pharma will work with University of Pennsylvania researchers to discover, develop and commercialize CAR immunotherapy drugs for cancer, while also establishing a joint R&D facility at the Philadelphia campus.

You may also be interested in...



Novartis’s Luxturna Deal Expands Gene Therapy Ambitions

By licensing Spark Therapeutics' Luxturna outside the US, Novartis is expanding its gene therapy ambitions into in vivo and non-oncological treatments.

CAR T-cell Therapy Shines In ALL; Safety Fix Highlighted At ASH

Emerging data for the immunotherapy class continues to impress, and investigators at the American Society of Hematology report success with managing the cytokine-release syndrome side effects.

Servier Links Up With Celladon For Potential Diabetes Drugs

Servier inks its second deal in less than two weeks, this time for potential diabetes candidates. While both deals are early, they mark the French biotech’s foray into two hot fields of research.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS074601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel